Active ingredientCrizotinibCat. No. P-C256-001CAS 877399-52-5Family · Pharmaceutical analytical standards
Crizotinib
An ALK and MET kinase inhibitor, approved in the United States in 2011 as the first ALK inhibitor for non-small cell lung cancer carrying a rearrangement of this gene. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was born as a MET inhibitor: from the discovery of the EML4-ALK fusion in lung cancer, in 2007, to its approval only four years passed, an unprecedented time.
Go to the active ingredient →Active ingredientCrizotinibCat. No. P-C256-001CAS 877399-52-5
Isotopically labelledCrizotinib-d5Cat. No. P-C256-002CAS 1395950-84-1
Isotopically labelledN-Nitroso Crizotinib-d5Cat. No. P-C256-003
NitrosamineN-Nitroso CrizotinibCat. No. P-C256-004
Impurity(S)-CrizotinibCat. No. P-C256-005CAS 1374356-45-2
ImpurityCrizotinib Impurity 1Cat. No. P-C256-006CAS 704-09-6
ImpurityCrizotinib Impurity 2Cat. No. P-C256-007CAS 1146614-42-7
Impurity2',4'-Dichloro-5'-fluoroacetophenoneCat. No. P-C256-008CAS 704-10-9
Impurity2-Keto CrizotinibCat. No. P-C256-009CAS 1415558-82-5
ImpurityCrizotinib Impurity 3Cat. No. P-C256-010CAS 877397-70-1
ImpurityCrizotinib Impurity 4Cat. No. P-C256-011CAS 1233484-06-4
ImpurityCrizotinib Impurity 5Cat. No. P-C256-012
ImpurityCrizotinib Impurity 6Cat. No. P-C256-013
ImpurityCrizotinib Impurity 7Cat. No. P-C256-014No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.